Wegovy Thigh Injection: Complete UK Guide to Technique and Safety

Wegovy thigh injection is a convenient method for administering semaglutide 2.4 mg, a once-weekly GLP-1 receptor agonist licensed by the MHRA for weight management in adults with obesity or overweight with comorbidities. The thigh offers excellent visibility and accessibility for self-administration, making it a popular choice amongst the three approved injection sites. Proper technique, including site rotation and correct subcutaneous placement, ensures optimal drug absorption and minimises local reactions. This guide provides comprehensive, evidence-based instructions for safe and effective Wegovy thigh injections, aligned with UK clinical guidance and NICE recommendations for specialist weight management services.

Understanding Wegovy Thigh Injections

Wegovy (semaglutide) is a once-weekly subcutaneous injection licensed by the MHRA for weight management in adults with obesity (BMI 30 kg/m² or above) or overweight (BMI 27 kg/m² or above) with at least one weight-related comorbidity.^[1] Licensed dose strengths include 2.4 mg and 7.2 mg; your prescriber will determine the appropriate strength for you. As a glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide works by mimicking the action of the naturally occurring GLP-1 hormone, which regulates appetite and food intake through effects on the brain's satiety centres.^[1][3]

In the UK, NICE recommends Wegovy as part of a specialist weight management service for adults with a BMI of at least 35 kg/m² (or 30 kg/m² with weight-related comorbidities), with appropriate adjustments for people from Black, Asian and minority ethnic groups.^[2] Treatment is typically limited to a maximum of 2 years.^[2]

The medication is administered using the Wegovy FlexTouch pen, a multi-dose dial-a-dose pre-filled pen with detachable needles. Each pen contains four weekly doses. The thigh is one of three recommended injection sites, alongside the abdomen and upper arm. Many patients find the thigh particularly convenient for self-administration, as it offers good visibility and accessibility. Upper arm injections may require assistance from a caregiver.

Subcutaneous injection allows for gradual absorption of semaglutide into the bloodstream, maintaining therapeutic levels throughout the week. The anterior (front) and lateral (outer) aspects of the thigh contain adequate subcutaneous tissue for proper drug delivery whilst avoiding muscle tissue and major blood vessels. Rotating injection sites within and between the approved areas is essential to prevent lipodystrophy (changes in fat tissue) and maintain consistent drug absorption.

Importantly, Wegovy should not be used during pregnancy. Women of childbearing potential should use effective contraception and stop Wegovy at least 2 months before a planned pregnancy. Breastfeeding is not recommended whilst taking Wegovy; discuss this with your prescriber or midwife.

Preparing for Your Wegovy Thigh Injection

Proper preparation is essential for safe and effective Wegovy administration. If preferred for comfort, you may remove your Wegovy FlexTouch pen from the refrigerator a short while before injection to allow it to approach room temperature. Do not use external heat sources to warm the pen.

Check the medication carefully before each injection. Examine the solution through the pen window, it should be clear and colourless or slightly yellow. Do not use the pen if the liquid appears cloudy, discoloured, or contains particles. Verify the expiration date on the pen label and ensure you have the correct dose strength as prescribed by your healthcare provider.

Gather your supplies in a clean, well-lit area:

• Your Wegovy FlexTouch pen

• Compatible pen needles (a new, sterile needle must be used for each injection)

• Alcohol wipes

• A sharps disposal container approved for home use

• Clean, dry hands

Hand hygiene is essential. Wash your hands thoroughly with soap and warm water, ensuring you clean between fingers and under nails. Dry hands completely with a clean towel.

Select and prepare your injection site on the front or outer thigh. The area should be free from bruises, scars, moles, or areas of broken or irritated skin. Avoid injecting into areas with lumps, swelling, or tenderness, and do not use the same spot as your previous injection. Clean the chosen site with an alcohol wipe and allow the skin to air dry completely before injecting.

Wegovy FlexTouch pens should be stored in a refrigerator (2 to 8°C) until first use. Once in use, the pen can be kept for up to 6 weeks when stored at a temperature below 30°C or in the refrigerator (2 to 8°C). Always remove the needle after each injection before storing the pen. Do not freeze the pen. Refer to the Patient Information Leaflet for full storage details.

Step-by-Step Guide to Injecting Wegovy in the Thigh

Wegovy is supplied as a FlexTouch multi-dose dial-a-dose pen. A new, sterile pen needle must be attached before each injection and removed and discarded afterwards. The pen is not disposed of after a single use; it is stored for subsequent weekly doses. Always follow the Instructions for Use (IFU) supplied with your pen. The steps below are a general guide:

1. Check the pen to ensure the medication appears clear and colourless or slightly yellow. Verify the expiration date and dose strength.

2. Attach a new pen needle by removing the protective tab, screwing the needle onto the pen, and removing both the outer and inner needle caps. Use a new sterile needle for every injection.

3. Prime the pen if this is your first injection from a new pen, following the priming steps in the IFU. Priming removes air from the cartridge and confirms the pen is working correctly.

4. Dial your prescribed dose using the dose selector until the dose counter shows the correct dose.

5. Position yourself comfortably, either sitting or standing, ensuring you have clear access to your thigh.

6. Choose your injection technique based on the amount of subcutaneous tissue present:

7. If you can pinch a fold of skin and fat, gently pinch the thigh between your thumb and fingers to create a raised area

8. If you have adequate subcutaneous tissue, you may inject without pinching

9. Insert the needle into the skin at a 90-degree angle (or as directed in the IFU) with a smooth, confident motion.

10. Press and hold the dose button fully until the dose counter returns to 0, then continue to hold the needle in the skin for the number of seconds specified in the IFU to ensure the full dose is delivered.

11. Remove the needle from the skin, then carefully replace the outer needle cap and unscrew the needle. Dispose of the used needle immediately in your sharps container.

12. Store the pen with the pen cap replaced, without a needle attached, in the refrigerator or at room temperature below 30°C for up to 6 weeks, as described in the Patient Information Leaflet.

Do not rub the injection site after administration. A small amount of bleeding or a drop of fluid at the injection site is normal, apply gentle pressure with a clean tissue if needed. Follow local guidelines for disposing of your sharps container when full.

Managing Side Effects and Injection Site Reactions

Local injection site reactions are generally mild and transient with Wegovy thigh injections. Common reactions include redness, itching, bruising, or mild swelling at the injection site, typically resolving within a few days without intervention. Applying a cool compress (not ice directly on skin) after injection may help reduce discomfort and swelling.

To minimise injection site reactions:

• Rotate injection sites consistently, never injecting in the same spot twice in succession

• Allow the alcohol wipe to dry completely before inserting the needle

• Use a smooth, confident technique rather than hesitant, slow penetration

• Avoid injecting into areas with existing bruises or irritation

Systemic gastrointestinal side effects are more common than injection site reactions with Wegovy. Nausea, vomiting, diarrhoea, constipation, and abdominal pain affect a significant proportion of patients, particularly during dose escalation.^[1][3] These effects typically diminish over time as your body adjusts to the medication. To manage gastrointestinal symptoms:

• Eat smaller, more frequent meals rather than large portions

• Avoid high-fat, fried, or heavily spiced foods

• Stay well hydrated, sipping water throughout the day

• Eat slowly and stop when comfortably satisfied

Seek medical advice if you are unable to keep fluids down, as dehydration can lead to kidney problems.

Hypoglycaemia risk is generally low with Wegovy monotherapy but increases if you take other diabetes medications.^[1] Be aware of symptoms including trembling, sweating, confusion, rapid heartbeat, or feeling faint. If you experience recurrent hypoglycaemia, contact your GP or diabetes specialist for medication review.

Document your injection sites using a body map or diary to ensure proper rotation and identify any patterns of reaction.

If you experience any suspected side effects, report them to the MHRA via the Yellow Card Scheme at www.^[1]gov.uk/yellowcard. This helps monitor the safety of medicines in the UK.

When to Seek Medical Advice

Seek immediate medical attention (call 999 or attend A&E) if you experience:

• Signs of severe allergic reaction (anaphylaxis): difficulty breathing, swelling of face, lips, tongue or throat, severe rash or hives, rapid pulse, dizziness or fainting

Contact NHS 111 or seek urgent GP advice if you develop:

• Severe, persistent abdominal pain (possibly radiating to the back), with or without vomiting, which may indicate pancreatitis^[1]

• Severe upper right abdominal pain, fever, or yellowing of skin or eyes (jaundice), which may suggest gallbladder problems

• Severe or persistent gastrointestinal symptoms preventing adequate fluid or food intake

• Signs of dehydration (dark urine, dizziness, reduced urination, extreme thirst)

Contact your GP if you notice:

• Persistent injection site reactions lasting more than one week

• Signs of infection at injection sites (increasing warmth, spreading redness, pus, fever)

• Recurrent hypoglycaemia if taking diabetes medications

• Unexplained visual changes or severe headaches

• Symptoms of depression or suicidal thoughts (rare but reported with this medicine class; seek help promptly)^[1]

Routine follow-up with your prescribing clinician is essential for monitoring treatment response, managing side effects, and adjusting doses appropriately. NICE recommends regular review of weight loss progress, with consideration of treatment discontinuation if less than 5% body weight loss is achieved after 6 months at maintenance dose.^[2] Treatment is typically limited to a maximum of 2 years.^[2]

If you miss a dose, and it is 5 days or fewer since the scheduled injection, take the missed dose as soon as possible. If more than 5 days have passed, skip the missed dose and take your next injection on the regular scheduled day. Check the current Patient Information Leaflet or speak to your pharmacist if you are unsure.

Never share your Wegovy pen with others, as this poses serious infection risks. Store unused pens in the refrigerator (2 to 8°C), do not freeze, and once in use keep the pen for up to 6 weeks at below 30°C or in the refrigerator. Always remove the needle after each injection before storing the pen. Refer to the Patient Information Leaflet for full storage details.

Women of childbearing potential should use effective contraception while taking Wegovy and stop treatment at least 2 months before a planned pregnancy. Wegovy should not be used during pregnancy, and breastfeeding is not recommended whilst taking this medicine.

Scientific References

1. Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC).
2. Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875].
3. Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Frequently Asked Questions